Abstract:You have accessJournal of UrologyProstate Cancer: Basic Research & Pathophysiology I (MP16)1 Apr 2020MP16-06 PUTATIVE TUMOR SUPPRESSOR ELL2 IS REQUIRED FOR PROLIFERATION AND SURVIVAL OF AR-NEGATIVE PROSTATE CANCER CELLS Zhi Wang*, Laura E. Pascal, Uma R Chandran, Srilakshmi Chaparala, Shidong Lyu, Ding Hui, Lin Qi, and Zhou Wang Zhi Wang*Zhi Wang* More articles by this author , Laura E. PascalLaura E. Pascal More articles by this author , Uma R ChandranUma R Chandran More articles by this author , Srilakshmi ChaparalaSrilakshmi Chaparala More articles by this author , Shidong LyuShidong Lyu More articles by this author , Ding HuiDing Hui More articles by this author , Lin QiLin Qi More articles by this author , and Zhou WangZhou Wang More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000841.06AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Elongation Factor For RNA Polymerase II, 2 (ELL2) was reported as a putative tumor suppressor in the prostate cancer. ELL2 is frequently down-regulated in prostatic adenocarcinoma specimens. Loss of ELL2 induced murine prostatic intraepithelial neoplasia and enhanced AR-positive prostate cancer cell proliferation. However, ELL2 gene was amplified or overexpressed in neuroendocrine prostate tumors, suggesting a potential oncogenic role for ELL2 in AR-negative neuroendocrine prostate cancer cells. In this study, we explored potential function of ELL2 in PC3 and DU145, two AR-negative prostate cancer cells with some neuroendocrine phenotype. METHODS: The role of ELL2 in PC3 and DU145 was studied by determining the impact of ELL2 knockdown. Genes regulated by ELL2 knockdown in PC3 cells was identified using RNA-Seq and bioinformatics. Expression of various genes were confirmed by western blot and quantitative real-time PCR. Cell growth were determined by BrdU, MTT and colony formation assays. The cell death was analyzed by Annexin V/7-AAD staining. Cell cycle was determined by flow cytometry. RESULTS: ELL2 knockdown inhibited proliferation in PC3 and DU145 cells, in contrast to the enhancement of proliferation in AR-positive LNCaP and C4-2 prostate cancer cells by ELL2 knockdown. RNA-Seq analysis showed an enrichment in genes associated with cell death and survival following ELL2 knockdown. The interferon-γ pathway was identified as the top canonical pathway comprising of 55.6% of the differentially expressed genes. ELL2 knockdown induced an increase in STAT1 and IRF1 mRNA and an induction of total STAT1 and phosphorylated STAT1 protein. Inhibition of cell proliferation by ELL2 knockdown was partly abrogated by siSTAT1 knockdown. Colony formation and MTT assay suggested that ELL2 knockdown could induce profound cell death in both PC3 and DU145 cells. Flow cytometry analysis showed that knockdown ELL2 indeed induced apoptosis and also caused S-phase arrest. CONCLUSIONS: ELL2 knockdown inhibited cell proliferation, induced S-phase arrest, promoted apoptosis in AR-negative PC3 and DU145 prostate cancer cells, which is accompanied by the induction of genes associated with cell death and survival as well as the interferon-γ pathway. This suggests a potential oncogenic role for ELL2 in AR-negative prostate cancer cells. The mechanisms by which ELL2 promotes AR-negative prostate cancer cell proliferation and survival may represent potential targets for the treatment of AR-negative prostate cancer. Source of Funding: This project was supported in part by NIH grant R01 CA186780 and R50 CA211242. © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e216-e216 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Zhi Wang* More articles by this author Laura E. Pascal More articles by this author Uma R Chandran More articles by this author Srilakshmi Chaparala More articles by this author Shidong Lyu More articles by this author Ding Hui More articles by this author Lin Qi More articles by this author Zhou Wang More articles by this author Expand All Advertisement PDF downloadLoading ...

NELL2 Modulates Cell Proliferation and Apoptosis via ERK Pathway in the Development of Benign Prostatic Hyperplasia.

Expression of Nkx3.1 Enhances 17 Beta-Estradiol Anti-Tumor Action in PC3 Human Prostate Cancer Cells

EGR1 Promotes Proliferation in Prostatic Hyperplasia Epithelial BPH-1 Cells

ELL2 Is Required for the Growth and Survival of AR-Negative Prostate Cancer Cells.

Prostaglandin E2 Mediates Up-regulation of ERRα Expression with BPH-1 Condition Medium in Prostatic Stromal Cells

Conditional deletion of ELL2 induces murine prostate intraepithelial neoplasia

MP06-05 UPREGULATED INTERLEUKIN 21 RECEPTOR ENHANCES PROLIFERATION AND EPITHELIAL-MESENCHYMAL TRANSITION PROCESS IN BENIGN PROSTATIC HYPERPLASIA

ELL2 Regulates DNA Non-Homologous End Joining (NHEJ) Repair in Prostate Cancer Cells.

Upregulated Interleukin 21 Receptor Enhances Proliferation and Epithelial-Mesenchymal Transition Process in Benign Prostatic Hyperplasia

Relationship between the Expression of Estrogen Receptor α and Basal Cell Dedifferentiation in Benign Prostatic Hyperplasia

THE RELATIONSHIP OF THE PROLIFERATION AND PHENOTYPIC MODULATION OF THE STROMAL CELLS AND THE EXPRESSION OF ESTROGEN RECEPTOR α IN BENIGN PROSTATIC HYPERPLASIA

Regulation of ELL2 Stability and Polyubiquitination by EAF2 in Prostate Cancer Cells.

Benign prostatic hyperplasia (BPH) epithelial cell line BPH-1 induces aromatase expression in prostatic stromal cells via prostaglandin E2.

Expression and regulatory effects on cancer cell behavior of NELL1 and NELL2 in human renal cell carcinoma

Inactivation of AR/TMPRSS2-ERG/Wnt Signaling Networks Attenuates the Aggressive Behavior of Prostate Cancer Cells

(058) Evaluation of Pathway Expression Following Down-Regulation of NELL1, a Potential Gene of Interest in Peyronie's Disease

MP16-06 PUTATIVE TUMOR SUPPRESSOR ELL2 IS REQUIRED FOR PROLIFERATION AND SURVIVAL OF AR-NEGATIVE PROSTATE CANCER CELLS

Estradiol promotes epithelial-to-mesenchymal transition in human benign prostatic epithelial cells.

c-Jun Transcriptional Regulates NPRL2 to Promote the Proliferation Activity of Prostate Cancer Cells via AKT/MDM2/p53 Signaling Pathway

Redox-Activatable Hyaluronic Acid-Ss-Mertansine Prodrug: Superior Drug Loading, Enhanced Toleration, and Targeted Breast Tumor Therapy

MP51-12 ELL2 DEFICIENCY UPREGULATES PD-L1 EXPRESSION VIA JAK2 SIGNALING IN PROSTATE CANCER CELLS